 
 
OUR LADY OF THE LAKE REGIONAL MEDICAL CENTER 
Policy Manual: Pharmacy Section/ 
Chapter: 
Medication Use, Storage 
and Handling 
Title: Oral Ketamine for Intractable Pain 
Policy 
Reference #: PH-03-33 
Supersedes #:  
Date of Origination: 1/19/2016 Review Date: 01/06/2025 
Revision Date: 3/3/2021 
    
 
 
PURPOSE: 
Oral ketamine will be used for analgesia in terminally ill adult patients with pain refractory to standard 
opioids and other adjunct therapies. This policy does not apply to patients needing sedation or acute pain 
relief in the intensive or emergency care areas. 
 
Relative Contraindications:  Ketamine will not be used in patients with increased intracranial 
pressure, active seizures, uncontrolled hypertension or severe cardiovascular disease, a history of 
psychosis, or while on monoamine oxidase inhibitors. 
 
POLICY: 
 
I.  Orders 
• Orders for oral ketamine for intractable pain control must be prescribed by a Palliative 
Care physician. 
• Patient must have a “Do Not Resuscitate” (DNR) order 
• All ketamine orders should include clear goals for pain scores as well as additional 
parameters for contacting the provider as necessary. 
• Patient must be on 5-West or PCU units at OLOLRMC 
• Only for patients 18 years of age or greater 
 
 
II. Oral Administration 
 
• Oral ketamine may be administered to adults on 5-West or PCU  
• Oral ketamine is prepared in the pharmacy from the IV formulation.  It is recommended 
that oral ketamine is further diluted at the bedside with cola or juice to minimize the bitter 
taste.   
 
III. Monitoring after Oral Administration 
 
a. Monitor the following at least every 4 hours: BP, HR, RR, sedation, pain levels 
b. For first dose or dose adjustment: monitor at baseline, every 20 minutes for the first hour, 
then every 2 hours X 2, then every 4 hours: BP, HR, RR, sedation, pain levels 
c.  Notify physician for any of the following: 
• Increase in BP greater than 20 mmHg above baseline 
• Increase in HR greater than 20 BPM above baseline, or HR greater than 100 BPM 
• RR less than 8 breaths/minute 
• Profound sedation  
 
• Unimproved pain score or ineffective symptom relief 
• Persistent nausea or vomiting 
• Seizures, agitation or restlessness 
• Unexpected change in vital signs or condition 
 
IV. Dosing: See Oral Ketamine for Intractable Pain Protocol for dosing information 
 
V. References 
 
• Barr J, Fraser GL, Puntillo K, et al.  Clinical practice guidelines for the management of pain, agitation, 
and delirium in adult patients in the critical care unit.  Critical Care Medicine.  2013;41:263-306. 
• Bell RF, Eccleston C, Kalso E.  Ketamine as adjuvant to opioids for cancer pain.  Journal of pain and 
symptom management.  2003;26(3):867-75. 
• Blonk, MI, Koder, BG, van den Bemt, P, et al. Use of oral ketamine in chronic pain management: A 
review. European Journal of Pain.  2010;14: 466–472. 
• Hardy J, Quinn S, Fazekas B, et al.  Randomized, double-blink, placebo-controlled study to assess the 
efficacy and toxicity of subcutaneous ketamine in the management of cancer pain.  Journal of Clinical 
Oncology.  2012;30(29):3611-7. 
• Jackson K, Ashby M, Martin P, et al.  “Burst” ketamine for refractory cancer pain: an open-label audit 
of 39 patients. Journal of Pain Symptom Management.  2001;22:834-42. 
• National comprehensive cancer network clinical practice guidelines in oncology - adult cancer pain 
guidelines.  Version 1.2015.  nccn.org. 
 
 
 